IMKELDI
Growthimatinib oral
NDAORALSOLUTION
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Mechanism of Action
protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from…
Loss of Exclusivity
LOE Date
Apr 27, 2040
172 months away
Patent Expiry
Apr 27, 2040
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 11957681 | Apr 27, 2040 | Product | — |